---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-044321"
form_type: "8-K"
ticker: "NXGL"
cik: "0001468929"
company_name: "NEXGEL, INC."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T14:48:47.080116+00:00"
event_type: "other"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NEXGEL forms partnership with STADA to distribute OTC health products in North America starting mid-2024

## Summary
- Partnership with STADA Arzneimittel AG, a European consumer health leader, for distribution and commercialization.
- Product launch expected mid-2024; brings established European OTC products to North American consumers.
- STADA reported 2022 group sales of EUR 3,797.2 million and EBITDA of EUR 884.7 million.
- NEXGEL will leverage its hydrogel expertise and contract manufacturing for the partnership.

## SEC filing metadata
- accession: 0001493152-23-044321
- form_type: 8-K
- ticker: NXGL
- cik: 0001468929
- company_name: NEXGEL, INC.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468929/000149315223044321/0001493152-23-044321-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468929/000149315223044321/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-044321
- JSON: https://secwatch.observer/filing/0001493152-23-044321.json
- Plain text: https://secwatch.observer/filing/0001493152-23-044321.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.